Zai gets Chinese rights to Five Prime's mAb

Five Prime Therapeutics Inc. (NASDAQ:FPRX) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to develop and commercialize FPA144

Read the full 174 word article

User Sign In